XML 15 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)    
Net loss $ (28,156,252) $ (24,876,157)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,649,699 1,610,855
Share-based payments for services 955,900 623,146
Equity based compensation 10,090,410 6,690,331
Common stock contributed to 401(k) plan 146,296 122,791
Shares issued for settlement of clinical research costs 0 1,769,500
Gain on short-term investments (6,578) 0
Loss on derivative instruments 991,562 3,565,347
Warrant inducement expense 0 805,753
Modification of warrants 24,387 5,554
(Increase)/decrease in assets:    
Receivables 0 (192,242)
Prepaid expenses 232,752 (969,219)
Supplies used for R&D and manufacturing (759,193) (4,648)
Deposits (248,712) 0
Increase/(decrease) in liabilities:    
Accounts payable 689,812 (761,675)
Accrued expenses 297,928 87,820
Due to employees 84,598 (166,310)
Other liabilities 22,459 (815)
Net cash used in operating activities (13,984,932) (11,689,969)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Net purchases of U.S. Treasury Bills 11,145,667 0
Purchases of property and equipment (8,628,648) (1,530,327)
Expenditures for patent costs 0 (39,975)
Net cash used in investing activities (19,774,315) (1,570,302)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock 47,363,426 13,992,439
Payments of stock issuance costs (207,673) (695,447)
Proceeds from the purchase of stock by officer 0 184,990
Proceeds from exercises of warrants and options 6,195,571 12,063,070
Proceeds from landlord funding of leasehold improvements 1,613,546 0
Payments on obligations under finance lease (756,817) (592,766)
Net cash provided by financing activities 54,208,053 24,952,286
NET INCREASE IN CASH AND CASH EQUIVALENTS 20,448,806 11,692,015
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 15,508,909 8,444,774
CASH AND CASH EQUIVALENTS, END OF PERIOD 35,957,715 20,136,789
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Property and equipment included in current liabilities 589,400 121,441
Capitalizable patent costs included in current liabilities 20,000 0
Changes to right of use assets and liabilities 551,444 399,032
Finance lease obligation included in accounts payable 1,328 775
Prepaid consulting services paid with issuance of common stock 292,792 11,706
Accrued consulting services to be paid with issuance of common stock 110,000 110,000
Fair value of warrants liabilities on date of exercise 3,838,471 3,035,325
Financing costs included in current liabilities 76,860 30,152
Cash paid for interest $ 876,779 $ 872,710